Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Novimmune S.A.. (1/11/16). "Press Release: Novimmune Completes CHF30 Million ($29.8 Million) Funding Round with Existing Shareholders". Geneva.

Organisation Organisation Novimmune S.A.
Products Product emapalumab (NI-0501)
  Product 2 venture capital
Index term Index term Novimmune–SEVERAL: investment, 201601 financing round CHF30m from existing shareholders
Person Person Holdener, Eduard (Ed) (Novimmune 201512– CEO before Roche CMO)
     


Broad Participation from Shareholder Base to Invest in Developing the Drug Pipeline, Including NI-0501 for Hemophagocytic Lymphohistiocytosis (HLH)


Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related disorders and cancer, today announced it has completed a CHF30 million ($29.8 million) funding round.

“We are delighted to have completed a CHF30 million funding round driven by major commitments from our lead investors that secured broad participation from our existing shareholder base,” said Novimmune Chairman and Chief Executive Officer Eduard Holdener. “This support from our shareholders demonstrates the confidence they have in the strength of our pipeline and in the future of the Company. We remain committed to further developing novel medicines to provide improved treatment options for patients suffering from rare and devastating diseases like Hemophagocytic Lymphohistiocytosis (HLH), as well as autoimmune and inflammatory diseases, and cancer.”


About Novimmune

Novimmune SA is a Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva.

   
Record changed: 2016-06-15

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Novimmune S.A.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top